Presentation: Each film-coated tablet contains Vonoprazan Fumarate equivalent to Vonoprazan 10 mg. It is usually available in blister packs.

Indications: Vonozan (Vonoprazan) is a potassium-competitive acid blocker (P-CAB) indicated for:

• Healing of gastric ulcer, duodenal ulcer, and reflux esophagitis.  
• Prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin administration.  
• Prevention of recurrence of gastric or duodenal ulcer during non-steroidal anti-inflammatory drug (NSAID) administration.  
• Adjunct to Helicobacter pylorieradicationin specific settings (gastric ulcer, duodenal ulcer, MALT lymphoma, idiopathic thrombocytopenic purpura, post-endoscopic resection of early gastric cancer, or H. pylori gastritis).
• Maintenance therapy of reflux esophagitis showing recurrence and recrudescence.
• Relief of heartburn associated with non-erosive Gastroesophageal Reflux Disease (GERD).

Dosage and Administration: Vonozan 10 mg tablet is usually administered orally once daily. The dosage and duration of treatment depend on the specific condition being treated and the physician's instructions.

• Prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin or NSAID administration: The usual adult dosage is one 10 mg tablet once daily.
• Maintenance therapy of reflux esophagitis: The usual adult dosage is 10 mg once daily. The dosage may be increased to 20 mg once daily if efficacy is inadequate.

Vonozan can be taken without regard to food. Swallow the tablet whole with water; do not chew or crush it.

Side Effects: Commonly reported side effects may include diarrhea, constipation, nausea, abdominal distension, and indigestion. Other potential side effects include rash, urticaria, and elevated liver enzymes. Allergic reactions, including drug hypersensitivity and anaphylactic shock, have been reported rarely.

Precautions: Vonozan is contraindicated in patients with known hypersensitivity to Vonoprazan or any of the excipients and in patients receiving atazanavir sulphate, nelfinavir, or rilpivirine hydrochloride. Exercise caution in patients with renal disorders, as a delay in excretion may occur, leading to increased blood concentration. Avoid use in patients with moderate to severe hepatic impairment. Symptomatic response to Vonozan does not preclude the presence of gastric malignancy. Long-term use may be associated with an increased risk of fundic gland polyps.

Use in Pregnancy and Lactation: Vonoprazan should be used in pregnant women or women with the possibility of being pregnant only if the potential benefit justifies the potential risk. It is advisable to avoid administering Vonoprazan to nursing mothers.

Storage: Store below 30°C, in a cool and dry place, protected from light. Keep out of reach of children.

Important Note: This information is for general knowledge and informational purposes only, and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.